+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rheumatology Therapeutics Market - Global Forecast 2026-2032- Product Image
Rheumatology Therapeutics Market - Global Forecast 2026-2032- Product Image
New

Rheumatology Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 193 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011655
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The rheumatology therapeutics market is undergoing rapid change as advanced clinical approaches, evolving regulatory frameworks, and shifting expectations for value-based care shape new opportunities and challenges for senior decision-makers. Effective navigation of this landscape requires strategic focus across innovation, operations, and stakeholder engagement.

Market Snapshot: Rheumatology Therapeutics Market

The global rheumatology therapeutics market is demonstrating steady growth, expanding from USD 35.45 billion in 2025 to USD 37.68 billion in 2026, with projections indicating a rise to USD 55.88 billion by 2032 at a CAGR of 6.71%. This upward trend highlights a surge in demand for targeted therapies, biosimilars, and the integration of digital health solutions. Leading market participants are actively adjusting their product pipelines and operational strategies to respond to shifting clinical requirements and global policy environments, seeking to capitalize on evolving opportunities worldwide.

Scope & Segmentation

  • Therapeutic Classes: Options include conventional DMARDs such as hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine, as well as IL-6 inhibitors, JAK inhibitors, and TNF inhibitors. Each class offers tailored mechanisms for cases ranging from initial management to those resistant to standard treatments.
  • Molecule Types: Biologics, biosimilars, and small molecules represent unique development pathways, market potential, and regulatory challenges, impacting both innovation timelines and commercialization strategies.
  • Indications: Major indications addressed include ankylosing spondylitis, gout, psoriatic arthritis, rheumatoid arthritis, and systemic lupus erythematosus. Differing prevalence and treatment response across these conditions influence therapy demand and clinical trial designs.
  • Route of Administration: Modalities such as intravenous, oral, and subcutaneous delivery affect both adherence and health system efficiency, also playing a significant role in patient and provider decision-making.
  • Patient Age Groups: Both adult and pediatric populations are served, each requiring distinct regulatory and safety strategies, especially regarding pediatric trial methodology and market introduction timing.
  • Distribution Channels: Therapies reach patients via offline and online channels. While digital pharmacies extend market accessibility, traditional settings maintain dominance for established products and specific patient segments.
  • Regional Scope: The market spans the Americas, Europe, Middle East and Africa, and Asia-Pacific, with each region defined by unique payer structures, regulatory requirements, and infrastructural capabilities shaping product access and uptake.
  • Technologies: Innovations such as biologic engineering, digital therapeutics, telehealth, and remote monitoring are becoming central to real-world data collection and sustained patient engagement, offering actionable insights to both manufacturers and payers.

Key Takeaways: Strategic Priorities in the Rheumatology Therapeutics Market

  • Innovation is advancing from generalized immunosuppressive approaches to precision therapies, allowing for improved patient stratification and tailored interventions that support optimal outcomes.
  • Emphasis on value-based care is leading payers and providers to prioritize safety monitoring, patient-reported outcomes, and comprehensive real-world evidence for informed decision-making and reimbursement.
  • Cost competition driven by greater biosimilar and small molecule use requires innovators to enhance differentiation through robust clinical programs, expanded patient support, and innovative delivery systems.
  • Collaboration with contract manufacturing organizations and regional partners is being leveraged to increase supply chain resilience, optimize regulatory compliance, and expand manufacturing capacity.
  • Adoption of digital health technologies, such as remote monitoring and telemedicine, is enhancing the efficiency of disease management, improving patient experiences, and supporting payer negotiations through robust data generation.
  • Targeted segment approaches and region-specific adaptation have become essential due to shifting healthcare systems and evolving procurement models in major markets.

Tariff Impact: Navigating 2025 Policy and Supply Chain Disruption

In 2025, anticipated tariff changes are projected to alter cost structures for imported active pharmaceutical ingredients and finished biologic products. Manufacturers must reconsider sourcing models, regional production, and supplier negotiations to mitigate cost increases and margin pressures. These adjustments can shift timelines for market access and require sustained investment in real-world evidence and differentiated service offerings, particularly as procurement expenses vary. Smaller players may need to enhance supply chain efficiency or forge new alliances to remain viable.

Methodology & Data Sources

This analysis synthesizes expert interviews with clinical, payer, and industry leaders, alongside reviews of regulatory documents, peer-reviewed studies, and clinical registries. Triangulation and stakeholder validation ensured segmentation accuracy and alignment with current market dynamics.

Why This Report Matters

  • Offers actionable direction to align clinical development and commercial plans within a complex regulatory and market environment.
  • Reveals areas of risk and opportunity emerging from supply chain dynamics, increased competition, and digital health expansion for strategic planning.
  • Equips executives to make informed decisions on investment priorities, market entry, and regional growth strategies for sustained progress.

Conclusion

Consistent performance in rheumatology therapeutics relies on aligning clinical advancement, robust real-world data generation, and operational flexibility. Strategic focus in these areas will define future value for all stakeholders in this evolving market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Rheumatology Therapeutics Market, by Therapeutic Class
8.1. Conventional Dmards
8.1.1. Hydroxychloroquine
8.1.2. Leflunomide
8.1.3. Methotrexate
8.1.4. Sulfasalazine
8.2. Il-6 Inhibitors
8.3. Jak Inhibitors
8.4. Tnf Inhibitors
9. Rheumatology Therapeutics Market, by Molecule Type
9.1. Biologics
9.2. Biosimilars
9.3. Small Molecules
10. Rheumatology Therapeutics Market, by Indication
10.1. Ankylosing Spondylitis
10.2. Gout
10.3. Psoriatic Arthritis
10.4. Rheumatoid Arthritis
10.5. Systemic Lupus Erythematosus
11. Rheumatology Therapeutics Market, by Route Of Administration
11.1. Intravenous
11.2. Oral
11.3. Subcutaneous
12. Rheumatology Therapeutics Market, by Patient Age Group
12.1. Adult
12.2. Pediatric
13. Rheumatology Therapeutics Market, by Distribution Channel
13.1. Offline
13.2. Online
14. Rheumatology Therapeutics Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Rheumatology Therapeutics Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Rheumatology Therapeutics Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Rheumatology Therapeutics Market
18. China Rheumatology Therapeutics Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. AbbVie Inc.
19.6. Aclaris Therapeutics, Inc.
19.7. Almirall, S.A.
19.8. Amgen Inc.
19.9. AstraZeneca PLC
19.10. Bristol-Myers Squibb Company
19.11. Chemomab Therapeutics Ltd.
19.12. Eli Lilly and Company
19.13. F. Hoffmann-La Roche Ltd.
19.14. Galapagos NV
19.15. Gilead Sciences, Inc.
19.16. GlaxoSmithKline plc
19.17. Johnson & Johnson Innovative Medicine
19.18. Mallinckrodt Pharmaceuticals plc
19.19. Novartis AG
19.20. Pfizer Inc.
19.21. Sanofi S.A.
19.22. Takeda Pharmaceutical Company Limited
19.23. Teva Pharmaceutical Industries Ltd.
19.24. UCB S.A.
List of Figures
FIGURE 1. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY LEFLUNOMIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY LEFLUNOMIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY LEFLUNOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SULFASALAZINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SULFASALAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY IL-6 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY IL-6 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOSIMILARS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOSIMILARS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GOUT, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GOUT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GOUT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 111. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 113. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 114. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 115. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 116. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 118. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 124. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 129. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 130. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 131. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 132. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 133. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 134. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 144. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 146. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 147. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 148. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 149. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 150. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 151. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 152. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 154. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 155. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 156. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 157. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 158. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 159. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 169. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 170. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 171. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 172. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 173. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 174. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 175. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 176. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 177. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 178. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 179. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 180. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 181. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 182. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 183. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 185. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 186. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 187. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 188. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 189. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 190. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 191. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 192. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 194. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 195. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 196. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 197. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 198. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 200. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 201. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 202. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 203. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
TABLE 204. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 205. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 206. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 207. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 208. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Rheumatology Therapeutics market report include:
  • AbbVie Inc.
  • Aclaris Therapeutics, Inc.
  • Almirall, S.A.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Chemomab Therapeutics Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Innovative Medicine
  • Mallinckrodt Pharmaceuticals plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

Table Information

Report AttributeDetails
No. of Pages193
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 37.68 Billion
Forecasted Market Value ( USD ) by 2032 $ 55.88 Billion
Compound Annual Growth Rate6.7%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Rheumatology Therapeutics - Global Strategic Business Report - Product Image

Rheumatology Therapeutics - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Rheumatology Therapeutics Market Report 2025 - Product Image

Rheumatology Therapeutics Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Anti-Rheumatic Drug Market - Forecasts from 2025 to 2030 - Product Image

Anti-Rheumatic Drug Market - Forecasts from 2025 to 2030

  • Report
  • 148 Pages
  • Global
From
Anti-Rheumatics Market Report by Type, Drug Class, Route of Drug Administration, Distribution Channel, and Region 2025-2033 - Product Image

Anti-Rheumatics Market Report by Type, Drug Class, Route of Drug Administration, Distribution Channel, and Region 2025-2033

  • Report
  • 143 Pages
  • Global
From

About the Anti Rheumatic Market

The Anti Rheumatic market is a subset of the Immune Disorders Drugs market, which focuses on the treatment of rheumatic diseases. These diseases are caused by an abnormal immune response, which can lead to inflammation and joint pain. Anti Rheumatic drugs are used to reduce inflammation and pain, as well as to prevent further damage to the joints. These drugs can be administered orally, intravenously, or topically. Commonly used Anti Rheumatic drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic response modifiers. Some companies in the Anti Rheumatic market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.